Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.
Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.
Social media provides benefits for teens, but there are also drawbacks.
Regional One Health is moving forward with its plans to transform The Commercial Appeal’s former 16-acre campus near Downtown Memphis into a more than $1 billion full academic medical center.
Health Care Heroes program recognizes extraordinary Memphis medical contributors.
Riverside Healthcare has announced the addition of Dr. Bakht Siddiqui to its team of child and adolescent psychiatrists, expanding mental health services for families in the region.
Tennessee’s health department awarded a $12 million grant aimed at closing health care gaps in rural areas to the University of Tennessee Health Science Center.
The University of Tennessee Health Science Center was chosen to receive $12 million from the Tennessee Department of Health to lead a four-year, statewide program aimed at improving health outcomes for rural Tennesseans.
